E. coli bacteria that have developed resistance to antibiotics will probably still be around even if we stop using antibiotics, as these strains have the same good chance as other bacteria of continuing to colonise the gut, according to a thesis at the Sahlgrenska Academy.
E. coli bacteria are found naturally in large quantities in our intestines. These bacteria do not normally cause disease, but there are several strains that can result in diarrhoea. In serious cases, they can also cause peritonitis and septicaemia.
The faeces of 128 Swedish infants were analysed in the studies underlying the thesis. The results show that 21% of E. coli strains in these infants’ gut flora were resistant to at least one type of antibiotic. Even children who had never been given antibiotics had resistant bacterial strains in their intestines.
“This is a growing problem, and it’s serious even when ordinary harmless bacteria develop resistance, as these genes can be transferred to more harmful bacteria,” says microbiologist Nahid Karami.
Many had thought that resistant bacteria would disappear if the use of antibiotics were to be reduced, but the thesis shows that E. coli strains carrying resistance genes are just as good at colonising the gut for long periods as sensitive strains.
”Our research suggests that there’s little cost to the bacteria from carrying a resistance gene, and this presumably means that this resistance will be retained for a long time by the bacteria in our gut flora even if we stop using antibiotics,” says Karami.
Bacteria have a natural ability to absorb and transfer resistance genes to other bacteria. The study discovered two cases of such transfers between E. coli strains found simultaneously in a child’s intestines. The first was in an infant who was treated with penicillin, and the second in an infant who was not treated with antibiotics.
“Our results suggest that the transfer of resistance genes in the gut flora may be very common, which makes the resistance issue much more serious, as genes can easily be transferred from bacteria in the normal flora to more harmful bacteria,” says Karami.
Source: Swedish Research Council
Related stories:
Evolution of virulence regulation in Staphylococcus aureus
Scientists have gained insight into the complex mechanisms that control bacterial pathogenesis and, as a result, have developed new theories about how independent mechanisms may have become intertwined during evolution. The research, published by Cell Press in the October 10th issue of the journal
Molecular Cell, may lead to strategies for developing more effective therapeutics against the human pathogen responsible for most of the antibiotic-resistant infections contracted in the community.
New vaccines may not reduce TB incidence
(PhysOrg.com) -- Despite the potential of new vaccines to prevent TB, new research shows that the removal of one strain of TB can allow a previously suppressed strain to succeed. Consequently, a vaccination program could result in the proliferation of strains more likely to be, or become, drug resistant, and could even result in an increased prevalence of the disease.
New way to make malaria medicine also first step in finding new antibiotics
University of Illinois microbiology professor William Metcalf and his collaborators have developed a way to mass-produce an antimalarial compound, potentially making the treatment of malaria less expensive.
Marijuana ingredients show promise in battling superbugs
Substances in marijuana show promise for fighting deadly drug-resistant bacterial infections, including so-called "superbugs," without causing the drug's mood-altering effects, scientists in Italy and the United Kingdom are reporting.
Stick with simple antibiotics for pneumonia to avoid super bugs, says researcher
Australian hospitals should avoid prescribing expensive broad-spectrum antibiotics for pneumonia to avoid the development of more drug-resistant super bugs, according to a University of Melbourne study.
Rifamycin antibiotics attack tuberculosis bacteria with walls, not signals
(PhysOrg.com) -- Amid concerns about the rising number of new tuberculosis cases worldwide, researchers led by Rockefeller University’s Seth A. Darst have reexamined and disproved a theory that describes how a potent class of antibiotics kills a deadly form of bacteria. The findings, which will appear in this week’s online issue of the
Proceedings of the National Academy of Sciences, not only bring scientists closer to understanding how these antibiotics work but also how the bacteria become resistant to their effects.
New study sheds light on how intracellular pathogens trigger the immune system
(PhysOrg.com) -- Disease-causing microbes like the food-borne bacterium Listeria monocytogenes specialize in invading and replicating inside their animal hosts' own cells, making them particularly tricky to defeat. Now, a new study led by biologists at the University of California, Berkeley, has identified a molecular alarm system in which the intracellular pathogen sends out signals that kick the immune response into gear.
New antibiotic beats superbugs at their own game
The problem with antibiotics is that, eventually, bacteria outsmart them and become resistant. But by targeting the gene that confers such resistance, a new drug may be able to finally outwit them. Rockefeller University scientists tested the new drug, called Ceftobiprole, against some of the deadliest strains of multidrug-resistant Staphylococcus aureus (MRSA) bacteria, which are responsible for the great majority of staphylococcal infections worldwide, both in hospitals and in the community.